U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H29N5O6
Molecular Weight 435.4742
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIMAZOSIN

SMILES

COC1=CC2=C(N=C(N=C2N)N3CCN(CC3)C(=O)OCC(C)(C)O)C(OC)=C1OC

InChI

InChIKey=YNZXWQJZEDLQEG-UHFFFAOYSA-N
InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)

HIDE SMILES / InChI

Molecular Formula C20H29N5O6
Molecular Weight 435.4742
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Trimazosin was originated by Pfizer and was licensed to Bristol-Myers Squibb worldwide except for Canada, Mexico and the USA. Trimazosin is a quinazoline antihypertensive agent structurally related to the selective alpha 1-adrenoceptor blocker prazosin. Trimazosin is an alpha adrenergic receptor antagonist. Compared with prazosin, trimazosin was a less potent but more efficacious hypotensive agent. At doses which caused equal or even greater hypotensive effects than those caused by prazosin, trimazosin caused less inhibition of pressor responses to phenylephrine. When administered during a maximum hypotensive response to prazosin, trimazosin caused an additional fall in pressure. Trimazosin is an effective antihypertensive when given by itself or in combination with a diuretic. Its ability to induce vasodilation without concomitant sodium retention or stimulation of the renin axis may be an important factor in its effectiveness. Trimazosin has the potential to cause sustained improvement in left ventricular function, both at rest and during exercise, in patients with chronic congestive heart failure (CHF).

Approval Year

PubMed

PubMed

TitleDatePubMed
The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.
1984 Jan-Feb
Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension.
1986
Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells.
2002 Nov
Patents

Patents

Sample Use Guides

Trimazosin was given for periods of at least 6 mo to 25 patients with mild to moderate essential hypertension. In doses of 300 to 900 mg dialy trimazosin alone led to blood pressure control (supine diastolic blood pressure less than 90 mm Hg with a fall of at least 10 mm Hg) in 16 patients (64%).
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 21:20:06 UTC 2023
Edited
by admin
on Thu Jul 06 21:20:06 UTC 2023
Record UNII
31L760807H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIMAZOSIN
INN   MI   WHO-DD  
INN  
Official Name English
TRIMAZOSIN [MI]
Common Name English
Trimazosin [WHO-DD]
Common Name English
trimazosin [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
WHO-VATC QC02CA03
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
WHO-ATC C02CA03
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
252-732-7
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
NCI_THESAURUS
C75059
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
ChEMBL
CHEMBL513301
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
WIKIPEDIA
TRIMAZOSIN
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
SMS_ID
100000076920
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
CAS
35795-16-5
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
EPA CompTox
DTXSID50189319
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
MESH
C005185
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
INN
3519
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
FDA UNII
31L760807H
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
MERCK INDEX
M978
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
2747
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
EVMPD
SUB11298MIG
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
DRUG BANK
DB09206
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
PUBCHEM
37264
Created by admin on Thu Jul 06 21:20:07 UTC 2023 , Edited by admin on Thu Jul 06 21:20:07 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY